Risk Factors Should Prompt Endoscopic Screening for High-risk Gastric Cancer
Early detection of high-risk, presymptomatic gastric cancer with endoscopic screening is associated with improved survival.
Diagnosis & Disease Information
Second-Line Trastuzumab Active in HER2-positive Advanced/Recurrent Gastric Cancer
Second-line treatment with paclitaxel/trastuzumab showed promising activity in trastuzumab-naïve patients with HER2-positive gastric cancer.
Poorer Survival Observed with MET-positive Stage IV Gastric Tumors
Patients with stage IV gastric tumors positive for MET protein expression have poorer survival than those without MET expression.
Second-Line Ramucirumab Plus Paclitaxel Improves Survival in Metastatic Gastric Cancer
Compared with paclitaxel alone, combining ramucirumab with paclitaxel increased survival in metastatic gastric cancer.
Risk of Esophageal, Gastric Cancer Linked to Socioeconomic Status, Weight
Adolescents’ weight and socioeconomic status may affect their subsequent risk of developing esophageal and gastric cancer.
Sequential Paclitaxel/S-1 Effective Adjuvant in Locally Advanced Gastric Cancer
Use of sequential paclitaxel followed by oral fluorinated pyrimidines results in a trend for better disease-free survival in locally advanced gastric cancer, found research presented at ASCO 2013.
Intraperitoneal and Intravenous Paclitaxel + Combination Chemotherapy Effective in Peritoneal Metastasis
Combination chemotherapy with S-1—oral tegafur, gimeracil, and oteracil potassium—and IV and intraperitoneal paclitaxel was well-tolerated and very effective in patients with gastric cancer and peritoneal metastasis, according to research presented at SSO 2013.
E-Cadherins and Diffuse Gastric Cancer
The E-cadherin (CDH1) gene plays an intricate role in the development of diffuse gastric cancer.
PPI Overuse: A Role in Gastric Cancer
In this week’s column, the author discusses the misuse of proton pump inhibitors by patients following a hospital discharge and the risk of gastric cancer they pose.
- Loading...
Loading...
Loading... 
Loading...